Rovi Is Weeks From Long-Acting Risperidone Filing
Long-Acting Letrozole Injectable At Phase I Stage
Executive Summary
Rovi hopes by the end of this year to file a hybrid marketing authorization application in Europe for a once-a-month sustained-release injectable formulation of risperidone. A US filing is scheduled for the first half of next year.